Trial Profile
A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Mar 2023 Planned End Date changed from 27 Feb 2023 to 27 Feb 2025.
- 15 Mar 2023 Planned primary completion date changed from 27 Feb 2023 to 27 Feb 2024.
- 07 Mar 2022 Planned End Date changed from 1 Feb 2022 to 27 Feb 2023.